KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $84.2 million.

  • CRISPR Therapeutics AG's Accumulated Expenses rose 7833.66% to $84.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.2 million, marking a year-over-year increase of 7833.66%. This contributed to the annual value of $41.1 million for FY2024, which is 940.33% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Accumulated Expenses stood at $84.2 million for Q3 2025, which was up 7833.66% from $73.7 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Accumulated Expenses peaked at $103.0 million during Q3 2022, and registered a low of $41.1 million during Q4 2024.
  • Its 5-year average for Accumulated Expenses is $73.6 million, with a median of $76.4 million in 2024.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Accumulated Expenses surged by 12744.02% in 2021 and then plummeted by 4164.03% in 2023.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Accumulated Expenses stood at $91.0 million in 2021, then dropped by 14.64% to $77.7 million in 2022, then tumbled by 41.64% to $45.3 million in 2023, then fell by 9.4% to $41.1 million in 2024, then skyrocketed by 104.96% to $84.2 million in 2025.
  • Its Accumulated Expenses stands at $84.2 million for Q3 2025, versus $73.7 million for Q2 2025 and $84.6 million for Q1 2025.